Intelligent Bio Solutions Inc.
INBS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.36 | 0.00 | 0.68 | 0.25 |
| FCF Yield | -3.35% | -2.67% | -3.33% | -3.67% |
| EV / EBITDA | -32.69 | -32.22 | -36.18 | -31.97 |
| Quality | ||||
| ROIC | -54.75% | -97.96% | -46.19% | -46.28% |
| Gross Margin | 46.62% | 39.77% | 46.84% | 36.73% |
| Cash Conversion Ratio | 0.95 | 0.71 | 1.08 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.05% | 34.42% | 53.38% | 104.07% |
| Free Cash Flow Growth | -20.62% | 12.68% | -18.69% | 2.24% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | 0.26 | 1.03 | 0.83 |
| Interest Coverage | -768.54 | -308.38 | -170.22 | -167.71 |
| Efficiency | ||||
| Inventory Turnover | 0.94 | 0.80 | 0.57 | 0.55 |
| Cash Conversion Cycle | 153.37 | 124.15 | -22.95 | 7.64 |